NCT00400569 · OUTCOME

Number of Participants With Serious Adverse Events (SAEs)

Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma · Source last updated 2012-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Determine the number of participants who experience Serious Adverse events while on sunitinib malate study.

Analysis population: All Participants

Sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Experimental: Sunitinib Malate (SU011248) Treatment	48

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Experimental: Sunitinib Malate (SU011248) Treatment	13	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Determine the number of participants who experience Serious Adverse events while on sunitinib malate study.

groups

param Type

NUMBER

population Description

All Participants

reporting Status

POSTED

time Frame

4 years, 7 months

title

Number of Participants With Serious Adverse Events (SAEs)

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice